Associated Banc-Corp announced it will release its third quarter 2026 financial results on October 22, 2026, after market close. The company will host a conference call at 4:00 p.m. Central Time for investors and analysts, accessible via webcast or phone. Financial tables and a slide presentation will be available on the company's website before the call, with an audio archive posted shortly after. This update is important for investors tracking the bank's performance and outlook in the Midwest financial sector.
Associated Banc-Corp's upcoming Q3 2026 earnings announcement is noted here with Pluang's Financials sector snapshot as of Oct 02, 2026 02:31 WIB. Among 85 priced Financials-sector US stocks, 36 rose and 48 fell. Banco Santander SA (SAN) traded at USD 13.24 with a 1-day change of -4.27%, showing 96% buy activity and a typical hold time of 54 days on Pluang. CleanSpark Inc (CLSK) was at USD 12.34, down 4.19%, with 100% buy activity and a 21-day hold time. ING Groep NV (ING) stood at USD 34.04, down 4.11%, with 88% buy activity and a 93-day hold time.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
